(RTTNews) - Retension Pharmaceuticals, Inc. (RTSN), a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, announced the pricing of its upsized initial public offering of 3.75 million shares at $12.00 per share. Retension Pharmaceuticals i
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.